Hospital
Mercy Medical Center-Centerville
Mercy Medical Center-Centerville was paid $3.24M by Medicaid between Jan 2018 and Nov 2024, across 83 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoMERCY MEDICAL CENTER-CENTERVILLE
CENTERVILLE, IA 52544
CENTERVILLE, IA 52544
33aNPI1356391635assigned 05/10/2006
33bProvider typeCritical Access Hospital
28Total paid$3.24M
24GClaims71,800
24DCodes billed83
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Iowa
Rank by total paid#7 of 79
Median peer was paid$801K
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,826 | $691K | |
| 2019 | 13,450 | $478K | |
| 2020 | 8,469 | $362K | |
| 2021 | 9,630 | $518K | |
| 2022 | 9,666 | $504K | |
| 2023 | 9,535 | $450K | |
| 2024incomplete | 4,224 | $240K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 6,287 | 5,554 | $601K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 5,108 | 4,283 | $494K |
| 80053 | Comprehensive metabolic panel | 7.7% | 7,266 | 6,208 | $249K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.6% | 2,256 | 1,800 | $246K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 7.2% | 2,155 | 1,908 | $234K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.7% | 11,015 | 9,259 | $184K |
| G0378 | Hospital observation service, per hour | 4.9% | 843 | 341 | $158K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.4% | 1,268 | 1,176 | $141K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.2% | 2,686 | 2,347 | $105K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 1,865 | 1,683 | $86K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.6% | 1,150 | 1,013 | $85K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.5% | 2,958 | 2,847 | $80K |
71 more codes
| 36415 | Collection of venous blood by venipuncture | 1.7% | 5,121 | $55K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 1,355 | $43K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.0% | 1,045 | $33K |
| 84484 | <1% | 1,432 | $30K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 536 | $27K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 804 | $26K |
| 81001 | <1% | 2,544 | $25K | |
| 83605 | <1% | 1,226 | $24K | |
| 82553 | <1% | 1,064 | $23K | |
| 82550 | <1% | 1,279 | $20K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 69 | $19K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 493 | $18K |
| 86140 | <1% | 1,147 | $16K | |
| 83880 | <1% | 448 | $15K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 250 | $15K |
| 80305 | <1% | 356 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 748 | $13K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 21 | $13K |
| 80061 | Lipid panel | <1% | 398 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 679 | $10K |
| 83735 | <1% | 529 | $9K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 68 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 245 | $9K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 40 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 64 | $8K |
| 73630 | <1% | 114 | $8K | |
| 83690 | <1% | 444 | $8K | |
| 87400 | <1% | 236 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,092 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 172 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 60 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 239 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 254 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 250 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 187 | $3K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 12 | $2K |
| 85652 | <1% | 208 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 354 | $2K |
| 96376 | <1% | 22 | $2K | |
| 81025 | <1% | 146 | $2K | |
| 81003 | <1% | 298 | $2K | |
| 94760 | <1% | 150 | $2K | |
| 87430 | <1% | 55 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 40 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 20 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 26 | $1K |
| 84146 | <1% | 25 | $965.60 | |
| 74021 | <1% | 14 | $956.65 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 17 | $877.68 |
| 83655 | <1% | 27 | $861.97 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 62 | $750.16 |
| 87581 | <1% | 40 | $725.97 | |
| 87486 | <1% | 40 | $721.73 | |
| 84439 | <1% | 40 | $615.24 | |
| 82150 | <1% | 27 | $493.59 | |
| 82077 | <1% | 18 | $458.55 | |
| 84550 | <1% | 34 | $388.33 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 22 | $375.65 |
| 82607 | <1% | 16 | $367.18 | |
| 80076 | <1% | 15 | $344.08 | |
| 85027 | <1% | 27 | $337.58 | |
| 82728 | <1% | 13 | $330.99 | |
| 87081 | <1% | 27 | $309.16 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 25 | $282.60 |
| 85018 | <1% | 25 | $256.33 | |
| 83550 | <1% | 13 | $199.92 | |
| 83540 | <1% | 13 | $161.48 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 16 | $108.12 |
| 87807 | <1% | 15 | $96.33 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16 | $94.40 |
| A9270 | Non-covered item or service | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCLAPP, NICOLE (PRESIDENT - MERCY CENTERVILLE MEDIC)
| Provider | Location | Paid |
|---|---|---|
| Mercy Medical Center-Centerville | Ottumwa, IA | $2.61M |
| Mercy Medical Center-Centerville | Centerville, IA | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.